致癌与突变杂志

抽象的

A Systemic Review of Clinical Trials on Dendritic-Cells Based Vaccine Against Malignant Glioma

Tang Chao, Wang Xiaowen, Li Zhiqi, Yue Qi, Yang Zixiao, Fan Kun, Dave SB Hoon and Hua Wei

The prognosis of patients with high grade gliomas (HGG) is quite poor, in spite of the standard combination of surgery, radiotherapy and chemotherapy. Recently, many clinical researchers have been focusing their efforts on the safety, feasibility and efficiency of dendritic cells (DCs) based vaccine against HGG. According to the literature search, 23 phase I/II clinic studies were picked and systemically reviewed to assess the application, the effect, and the future of DC vaccine for HGG. DC vaccine appears to have potential to increase overall survival with minimal complications. However, there still remains to be many challenges during vaccination, such as targeting specific/associated antigens, adjuvants, clinical status, and the evaluation of the response.